Abstract Library

#4502 Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression

Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.

Conference:

Presenting Author: Avanthay S

Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,

Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,

#4172 Hormonally characterised NF-PanNETs and their clinicopathological features

Introduction: PanNETs show pronounced hormonal heterogeneity. The expression of certain hormones may associate with functional syndromes, but also with histological and genetic features. However, detailed studies of hormonal patterns in PanNETs correlated to morphological and clinical data are lacking.

Conference:

Presenting Author: Moser E

Authors: Moser E, Ito A, Vogel L, Steiger K, Scheidhauer K,

Keywords: Neuroendocrine Tumor, hormonal expression, subtypes, outcome, transcriptional factors,

#3376 Usefulness of corrected SUV max change in metastatic NET lesions (before and after PRRT) obtained by [68Ga]Ga-DOTA-TATE PET/CT as a prognostic factor

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapeutic option for metastatic neuroendocrine tumor (NET)therapy. The high heterogeneity of the somatostatin receptors (SSTR) density in different NET metastatic lesions and inside single tumors probably influence an clinical outcome. Some studies suggest the response to PRRT assessed on the basis of imaging of SSTR may have a predictive value.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kania-Kuc A, Al Maraih I, Hubalewska-Dydejczyk A,

Keywords: PRRT, NET, outcome, 68Ga-DOTATATE PET/CT, SSTR expression,

#2965 Molecular Signature of Rectal Neuroendocrine Neoplasia

Introduction: Rectal neuroendocrine tumors are rare neuroendocrine neoplasias (NEN). Little is known about prevalence and type of somatostatin receptor subtypes (sstr) expression and somatic mutations in relation to long-term clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Unger N, Theurer S, Herold T, Weber F, Dralle H,

Keywords: Somatic Mutations, NGS, Somatostatin receptor subtypes, Intestinal NEN,

#2902 DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value

Introduction: Estimating prognosis of pancreatic neuroendocrine tumor (PNET) patients remains challenging. Mutation status of DAXX/ATRX/MEN1, histone modification patterns and immunohistochemistry for relevant transcription factors, including PDX1, were recently used to perform subtyping and distinguished two main types, A and B. These subtypes are linked to cell-of-origin and associated with clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Boons G, Vandamme T, Ibrahim J, Schepers A, Roeyen G,

Keywords: Pancreatic Neuroendocrine Tumor, DNA Methylation, Prognostic Biomarker,